date,title,source
Oct-22-18,"Investor Expectations to Drive Momentum within ChannelAdvisor, WideOpenWest, Arcos Dorados, Mesoblast, Ferrari N.V, and Weatherford International  Discovering Underlying Factors of Influence",GlobeNewswire
Oct-24-18,Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa,GlobeNewswire
Nov-09-18,Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions,GlobeNewswire
Nov-15-18,"Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights",GlobeNewswire
Nov-15-18,"Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018",GlobeNewswire
Nov-26-18,Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China,GlobeNewswire
Nov-29-18,"Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Dec-13-18,Meetings Held With FDA Support Mesoblasts Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD,GlobeNewswire
Dec-19-18,Mesoblast Makes Executive Appointment to Drive Product Commercialization,GlobeNewswire
Dec-24-18,Mesoblast to Present at 2019 Biotech Showcase in San Francisco,GlobeNewswire
Dec-28-18,Mesoblast Corporate Review,GlobeNewswire
Jan-07-19,Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco,GlobeNewswire
Jan-07-19,Phase 3 Trial of Mesoblasts Cell Therapy in Chronic Heart Failure Completes Recruitment,GlobeNewswire
Jan-14-19,Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs,GlobeNewswire
Feb-04-19,"New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast  Consolidated Revenues, Company Growth, and Expectations for 2019",GlobeNewswire
Feb-13-19,"Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018",GlobeNewswire
Feb-19-19,Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure,GlobeNewswire
Feb-20-19,"Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018",GlobeNewswire
Mar-13-19,Mesoblast Features at Upcoming U.S. Investor Conferences,GlobeNewswire
Mar-22-19,U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman,GlobeNewswire
Mar-25-19,Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa,GlobeNewswire
Mar-26-19,Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients,GlobeNewswire
Apr-05-19,Mesoblast to Present at Upcoming Global Life Sciences Conference in London,GlobeNewswire
